E. Errichetti, “Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial”, Acta Derm Venereol, vol. 104, p. adv41053, Sep. 2024.